During the corresponding time, Guardant Health Inc recorded a revenue increase by 44.33 % year on year, sequentially revenue grew by 11.04 %. While revenue at the Guardant Health Inc 's corporate clients
Guardant Health Inc's Comment on Sales, Marketing and Customers
The company provides products for clinical and biopharmaceutical markets to support patient care throughout various stages of disease. Its Guardant360 CDx test is FDA-approved as a companion diagnostic for multiple cancer treatments, including non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, aiding in the identification of patients who may benefit from specific therapies. The Guardant360 Liquid test analyzes over 740 genes to assist advanced cancer patients in selecting therapy options without the need for invasive biopsies. The company partners with cancer centers, research organizations, distributors, laboratory companies in Europe and Asia, and electronic medical record providers to improve customer experience and facilitate global commercialization. Its market segments include oncology professionals, advanced cancer patients, and biopharmaceutical companies marketing targeted therapies. Customers and markets referenced in filings include BRAFTOVI®, ENHERTU®, INLURIYO™, LUMAKRAS™, ORSERDU™, RYBREVANT®, and TAGRISSO®.
PALO ALTO, Calif. In a landmark development for precision oncology, Guardant Health, Inc. (Nasdaq: GH) has announced groundbreaking findings related to its Shield blood test for colorectal cancer (CRC) screening. A recent real-world study published in Current Medical Research and Opinion indicates that the Shield test boasts a remarkable patient adherence rate of 95% among a cohort of 20,000 patients. This statistic underscores Shield s potential role in revolutionizing CRC screening for average-risk adults aged 45 and older, especially as it is the first blood test to receive U.S. Food and Drug Administration (FDA) approval as a primary screening option for this demographic.The significance of this achi...
Guardant Health s Strategic Move: A $250 Million Public Offering to Fuel GrowthIn a significant move, Guardant Health, Inc., a trailblazer in precision oncology, has announced the commencement of an underwritten public offering aimed at raising $250 million through the sale of its common stock. The ambitious initiative, disclosed on October 25, 2023, reflects the company’s strategy to bolster its financial standing and support its expansive growth ambitions. Additionally, Guardant Health plans to provide underwriters with a 30-day option to purchase an extra $37.5 million in shares, potentially increasing the total proceeds to $287.5 million. The Facts1. Offering Scale : Guardant Health is seeking to ge...
In a significant breakthrough in the fight against early-stage breast cancer, Guardant Health, Inc. has announced promising results from its recent LIBERATE study, published in the esteemed journal ESMO Open. The study highlights the performance of Guardant Reveal, a minimal residual disease (MRD) blood test that employs advanced epigenomic (methylation) analysis to detect circulating tumor DNA. This could be a game changer in predicting cancer recurrence, providing patients and oncologists with critical insights into the efficacy of treatment regimens early in the disease course.According to the findings, Guardant Reveal demonstrated high clinical validity in identifying patients at risk of recurrence, mark...
Guardant Health, Inc. (Nasdaq: GH), a prominent player in the precision oncology sector, has recently announced that its innovative Shield multi-cancer detection (MCD) test has been selected by the National Cancer Institute (NCI) for inclusion in its Vanguard study. This significant development highlights the increasing importance of emerging technologies in cancer detection and screening.The NCI’s Vanguard study aims to explore the feasibility of integrating MCD tests in future clinical trials focused on cancer screening. Multi-cancer detection tests, like those developed by Guardant Health, utilize blood samples to screen for multiple oncology types simultaneously, offering a potentially game-changing ap...
Liquid Biopsy-Guided Treatment Using Guardant360 CDx Demonstrates Double Survival Rates for Patients with Advanced Cancer: Results from SCRUM-Japan GOZILA Study Published in Nature Medicine PALO ALTO, Calif. Guardant Health, Inc. (Nasdaq: GH), a frontline precision oncology company, recently showcased groundbreaking findings from their SCRUM-Japan GOZILA study. Published in the esteemed peer-reviewed journal Nature Medicine, the study concluded that patients with advanced cancer could potentially double their survival rates when receiving liquid biopsy-guided treatment based on Guardant360 CDx results.Guardant360 CDx, a comprehensive liquid biopsy, plays a crucial role in providing detailed genomic inform...
Guardant Health Set to Showcase Breakthroughs in Precision Oncology at ESMO 2024 PALO ALTO, Calif. Guardant Health, Inc. (Nasdaq: GH) is poised to make a significant impact at the upcoming European Society for Medical Oncology Congress (ESMO), which will take place from September 13 to 17, 2024, in Barcelona, Spain. As a leader in precision oncology, the company will present groundbreaking data from a series of studies that highlight the effectiveness of its innovative technologies in treating various advanced tumor types.Among the key presentations will be findings from the Guardant Reveal test, a state-of-the-art minimal residual disease (MRD) assessment tool, which is set to revolutionize treatment para...
Guardant Health and Policlinico Gemelli Forge Alliance to Pioneer Liquid Biopsy Services in Italy In an era defined by brisk advancements in medical science, it is with notable excitement that we report the recent collaboration betwixt Guardant Health, Inc. and the renowned Agostino Gemelli University Polyclinic Foundation IRCCS (Policlinico Gemelli) in Italy. This alliance aims to inaugurate an in-house liquid biopsy testing service, an undertaking poised to significantly uplift diagnostics within the hospital’s precincts.Guardant Health, domiciled in the enlightened borough of Palo Alto, California, stands as an epitome of innovation in the realm of precision oncology. With its shares exchanged under the...
In an era where precision oncology is transforming cancer care, the recent findings from Guardant Health offer a beacon of hope for colorectal cancer (CRC) patients and their healthcare providers. The publication of the COSMOS (COnquer Solid Malignancies by blOod Screening) study in Clinical Cancer Research underscores the validation of the Guardant Reveal liquid biopsy test s efficacy in predicting CRC recurrence. Coupled with an enhanced version of the Guardant360 test, these developments mark significant advancements in liquid biopsy technology, promising improved outcomes for patients navigating the complexities of cancer diagnosis and treatment. Guardant Reveal and the COSMOS Study’s Groundbreaking ...
Guardant Health Introduces Groundbreaking Upgrade to Liquid Biopsy Test, Revolutionizing Cancer Diagnosis and TreatmentIn a groundbreaking announcement, precision oncology company, Guardant Health, has unveiled a major upgrade to its market-leading liquid biopsy test, Guardant360. The enhanced test now evaluates biomarkers in an impressive 739 genes, representing a ten-fold increase from the previous version. This significant improvement allows for unprecedented precision in characterizing cancer, enabling more accurate diagnosis and tailored treatment strategies.Liquid biopsy is a non-invasive diagnostic technique that analyzes genetic material circulating in the bloodstream, providing valuable insights int...
Guardant Health s Shield Blood Test Receives Strong FDA Committee Recommendation for Colorectal Cancer ScreeningPALO ALTO, Calif. - In a groundbreaking development for cancer screening, Guardant Health, a leading precision oncology company, has announced that the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration s (FDA) Medical Devices Advisory Committee strongly recommends approval of the company s Shield blood test for colorectal cancer (CRC) screening. This non-invasive screening option is specifically aimed at adults aged 45 and older who are at average risk for the disease.The recommendation comes as a significant milestone for Guardant Health and emphasizes the potential of...
Guardant Health Inc’s Comment on Sales, Marketing and Customers
The company provides products for clinical and biopharmaceutical markets to support patient care throughout various stages of disease. Its Guardant360 CDx test is FDA-approved as a companion diagnostic for multiple cancer treatments, including non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, aiding in the identification of patients who may benefit from specific therapies. The Guardant360 Liquid test analyzes over 740 genes to assist advanced cancer patients in selecting therapy options without the need for invasive biopsies. The company partners with cancer centers, research organizations, distributors, laboratory companies in Europe and Asia, and electronic medical record providers to improve customer experience and facilitate global commercialization. Its market segments include oncology professionals, advanced cancer patients, and biopharmaceutical companies marketing targeted therapies. Customers and markets referenced in filings include BRAFTOVI®, ENHERTU®, INLURIYO™, LUMAKRAS™, ORSERDU™, RYBREVANT®, and TAGRISSO®.
Sources:
Guardant Health Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Guardant Health Inc’s corporate clients.
For your research, we’ve provided 9 tables on Guardant Health Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
126.59 %